Evogene (NASDAQ: EVGN) plans CFO change as VP Finance steps up to new role

Rhea-AI Filing Summary

Evogene Ltd. reports a planned change in its senior finance leadership. Chief Financial Officer Yaron Eldad will resign effective March 31, 2026, for personal reasons, and the company states there was no disagreement regarding its operations, policies, or practices. VP Finance Polina Ravzin, who has served in that role since 2022 and previously held finance positions at DSIT Solutions Ltd. and Acorn Energy Inc., will continue as VP Finance while also taking on CFO responsibilities.

Insights

Corporate governance and leadership-transition analyst

Evogene discloses a planned CFO departure with an internal finance leader stepping into the role.

Evogene is implementing a finance leadership transition, with CFO Yaron Eldad set to resign effective March 31, 2026, citing personal reasons. The company explicitly notes that his resignation does not stem from any disagreement on operations, policies, or practices, which helps frame this as a non-dispute-driven change.

Responsibility for the CFO function will shift internally to VP Finance Polina Ravzin, who has been with the company since 2022 and previously served in senior finance roles at DSIT Solutions Ltd. and Acorn Energy Inc. An internal appointment may support continuity in reporting and finance processes, but the actual impact will depend on how effectively responsibilities are combined and managed over time.

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-36187

EVOGENE LTD.

  (Translation of Registrant’s Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

Changes in Management

Evogene Ltd., or the Company, reports changes in its management.

Mr. Yaron Eldad, the Company’s Chief Financial Officer, notified his resignation from his position effective as of Mach 31, 2026. The resignation of Mr. Eldad was due to personal reasons and was not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company.

Ms. Polina Ravzin, the Company’s VP Finance, will continue in such position and will also assume the responsibilities of the CFO. Ms. Ravzin has served as the Company’s VP Finance from 2022. Prior to joining the Company, Ms. Ravzin served as controller and assistant to the CFO at DSIT Solutions Ltd. and Acorn Energy Inc. (NASDAQ/OTCQB: ACFN).

Evogene expresses its gratitude to Mr. Eldad for his contributions during his tenure and wishes Ms. Ravzin success with her new responsibilities.

This Form 6-K is incorporated by reference into the registration statements on Form F-3 (Securities and Exchange Commission (“SEC”) File No. 333-277565), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443, 333-203856, 333-286197 and 333-286197) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 15, 2026 EVOGENE LTD.
(Registrant)

By: /s/ Yaron Eldad
Yaron Eldad
Chief Financial Officer

FAQ

What management change did Evogene (EVGN) report in this Form 6-K?

Evogene reported that its Chief Financial Officer, Mr. Yaron Eldad, has notified the company of his resignation from the CFO position, effective March 31, 2026.

Why is Evogene CFO Yaron Eldad resigning?

The company states that Mr. Eldad’s resignation is due to personal reasons and is not the result of any disagreement with Evogene regarding its operations, policies, or practices.

Who will assume CFO responsibilities at Evogene after March 31, 2026?

Ms. Polina Ravzin, Evogene’s VP Finance, will continue in that role and also assume the responsibilities of the CFO.

What is the background of Evogene’s new finance leader, Polina Ravzin?

Ms. Ravzin has served as Evogene’s VP Finance since 2022. Before joining Evogene, she was controller and assistant to the CFO at DSIT Solutions Ltd. and Acorn Energy Inc. (NASDAQ/OTCQB: ACFN).

Did Evogene indicate any disagreements related to the CFO’s resignation?

No. Evogene specifically states that Mr. Eldad’s resignation was not due to any disagreement with the company on matters related to its operations, policies, or practices.

How is this Form 6-K used in Evogene’s existing SEC registrations?

The Form 6-K is incorporated by reference into Evogene’s registration statements on Form F-3 (File No. 333-277565) and multiple Form S-8 registration statements, becoming part of those documents from the date it is submitted, unless later superseded.